Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

• Published in: Breast (Edinburgh) 2022-10, Vol.65, p.172-178
• Main Authors: Sim, Sung Hoon, Kim, Jeong Eun, Kim, Min Hwan, Park, Yeon Hee, Kim, Jee Hyun, Suh, Koung Jin, Koh, Su-Jin, Park, Kyong Hwa, Kang, Myoung Joo, Ahn, Mi Sun, Lee, Kyoung Eun, Kim, Hee-Jun, Ahn, Hee Kyung, Kim, Han Jo, Park, Keon Uk, Byun, Jae Ho, Park, Jin Hyun, Lee, Gyeong-Won, Lee, Keun Seok, Sohn, Joohyuk, Jung, Kyung Hae, Park, In Hae
• Format: Article
• Language: English
• Subjects: Clinical trial; ctDNA; HER2 positive; Metastatic breast cancer; Original; Trastuzumab biosimilar
• ISSN: 0960-9776; 1532-3080
• DOI: 10.1016/j.breast.2022.08.002

We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies. •Treatment of HER2-positive breast cancer is rapidly evolving with the development of new agents. However, treatment options are still limited after progression with proven anti-HER2 therapies.•The combination of chemotherapy with a trastuzumab biosimilar, Herzuma®, was effective and safe in patients with heavily pre-treated HER2+ MBC.•Duration of response to previous anti-HER2 therapy, PIK3CA and ERBB2 mutations were associated with clinical efficacies of trastuzumab biosimilar plus chemotherapy.